Emergent BioSolutions Inc. (EBS)
Market Cap | 128.94M |
Revenue (ttm) | 1.05B |
Net Income (ttm) | -760.50M |
Shares Out | 52.20M |
EPS (ttm) | -14.85 |
PE Ratio | n/a |
Forward PE | 7.94 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,493,862 |
Open | 2.500 |
Previous Close | 2.450 |
Day's Range | 2.370 - 2.520 |
52-Week Range | 1.420 - 13.670 |
Beta | 1.22 |
Analysts | Buy |
Price Target | 5.00 (+102.43%) |
Earnings Date | Mar 6, 2024 |
About EBS
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of d... [Read more]
Full Company ProfileFinancial Performance
In 2023, EBS's revenue was $1.05 billion, a decrease of -6.10% compared to the previous year's $1.12 billion. Losses were -$760.50 million, 259.4% more than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for EBS stock is "Buy." The 12-month stock price forecast is $5.0, which is an increase of 102.43% from the latest price.
News
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2023.
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial re...
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global company providing solutions that address public health threats and delivering life-extending produ...
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
GAITHERSBURG, Md., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a global company providing solutions that address public health threats and brings lifesaving, life-extending pr...
Emergent BioSolutions stock pulls back, after rallying last week in wake of Biden administration's endorsement of overdose medications
Shares of Emergent BioSolutions Inc. EBS slumped 2.8% in afternoon trading Tuesday, after surging more than 11% over the past two sessions, including Friday's 8.3% rally. The rally to end last week ca...
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
GAITHERSBURG, Md., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administr...
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
GAITHERSBURG, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on November 16, 2023, the New York Stock Exchange (NYSE) sent a notice that the company...
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
GAITHERSBURG, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported selected financial results for the third quarter ended September 30, 2023. The selected finan...
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
GAITHERSBURG, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) has rescheduled its conference call to Wednesday, November 8, at 5:00 pm eastern time to discuss the financi...
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 2, 2023, at 5:00 pm eastern time to discuss the financial ...
Emergent BioSolutions Partners with Emmitt Smith to Launch Ready to Rescue Campaign to Help Save Lives Amidst Rising Opioid Epidemic
Professional Football Hall of Famer partners with Emergent to raise awareness of the dangers of opioid use and the importance of being prepared with NARCAN® Nasal Spray The life-saving medicine is ava...
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October ...
Emergent Biosolutions to make Narcan opioid overdose treatment available without prescription starting in September
Emergent Biosolutions Inc. EBS, -7.92% said Wednesday its Narcan nasal spray that's an antidote for an opioid overdose will be available without a prescription starting in September. The Gaithersburg,...
Emergent BioSolutions' NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
GAITHERSBURG, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced NARCAN® Naloxone HCl Nasal Spray 4 mg will be available on shelves nationwide and online be...
Kenvue Set to Join S&P 500; Advance Auto Parts to Join S&P SmallCap 600
NEW YORK , Aug. 21, 2023 /PRNewswire/ -- Kenvue Inc. (NYSE: KVUE) will replace Advance Auto Parts Inc. (NYSE: AAP) in the S&P 500, and Advance Auto Parts will replace Emergent BioSolutions Inc. (NYSE:...
2023 Layoff Tracker: Tyson Foods, Emergent BioSolutions Cut Hundreds Of Jobs
Layoffs continue apace after more than 136,000 employees were cut by major U.S. companies in the first quarter of 2023.
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
GAITHERSBURG, Md., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2023. It also announced strategic ste...
2023 Layoff Tracker: Emergent BioSolutions Cuts 400 Jobs
Layoffs continue apace after more than 136,000 employees were cut by major U.S. companies in the first quarter of 2023.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Emergent BioSolutions Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK , Aug. 8, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...
Emergent BioSolutions to lay off about 400 employees
Emergent BioSolutions Inc said on Tuesday it plans to lay off about 400 employees across all businesses and cut back operations at some of its facilities.
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
Actions bring sharpened focus on MCM and NARCAN® Nasal Spray products Expected to improve operational efficiencies and deliver annual cost savings over $100 million annually GAITHERSBURG, Md., Aug. 08...
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
GAITHERSBURG, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a 10-year contract by the Biomedical Advanced Research and Development A...
US FDA approves second over-the-counter opioid overdose reversal drug
The U.S. Food and Drug Administration has approved the prescription-free sale of the second opioid overdose reversal drug, its manufacturer Harm Reduction Therapeutics said on Friday.
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
GAITHERSBURG, Md., July 25, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 8, 2023, at 5:00 pm eastern time to discuss the financial res...
US FDA approves Emergent BioSolutions' anthrax vaccine
Emergent BioSolutions said on Thursday the U.S. Food and Drug Administration has approved its anthrax vaccine.